SELLAS Life Sciences (SLS) Receives FDA Orphan Drug Designation for Galinpepimut-S (GPS) for Treatment of MM
Tweet Send to a Friend
SELLAS Life Sciences Group Inc. (Nasdaq: SLS) (“SELLAS”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
